On the contrary, overexpression or inhibition of miR-29b, respectively, antagonized or potentiated the anti-myeloma effects of the pan-HDAC inhibitor SAHA confirming that HDAC4-miR-29b axis modulates the effects of anti-myeloma drugs. Here, HDAC4 is linked to plasma cell myeloma.